Jun Hayashi

A&G Pharmaceutical, Inc. develops and creates monoclonal antibodies to cancer-specific targets. It focuses on a near-term opportunity to complete development of and commercialize two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. The firm's product Theranostics develops molecular diagnostic tests in tandem with targeted therapeutics. The company was founded by Jun Hayashi, Ginette Serrero, and Gordon H. Sato in June 2000 and is headquartered in Columbia, MD.

A&G Pharmaceutical, Inc. develops and creates monoclonal antibodies to cancer-specific targets. It focuses on a near-term opportunity to complete development of and commercialize two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. The firm's product Theranostics develops molecular diagnostic tests in tandem with targeted therapeutics. The company was founded by Jun Hayashi, Ginette Serrero, and Gordon H. Sato in June 2000 and is headquartered in Columbia, MD.

A&G Pharmaceutical, Inc. develops and creates monoclonal antibodies to cancer-specific targets. It focuses on a near-term opportunity to complete development of and commercialize two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. The firm's product Theranostics develops molecular diagnostic tests in tandem with targeted therapeutics. The company was founded by Jun Hayashi, Ginette Serrero, and Gordon H. Sato in June 2000 and is headquartered in Columbia, MD.

A&G Pharmaceutical, Inc. develops and creates monoclonal antibodies to cancer-specific targets. It focuses on a near-term opportunity to complete development of and commercialize two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. The firm's product Theranostics develops molecular diagnostic tests in tandem with targeted therapeutics. The company was founded by Jun Hayashi, Ginette Serrero, and Gordon H. Sato in June 2000 and is headquartered in Columbia, MD.

A&G Pharmaceutical, Inc. develops and creates monoclonal antibodies to cancer-specific targets. It focuses on a near-term opportunity to complete development of and commercialize two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. The firm's product Theranostics develops molecular diagnostic tests in tandem with targeted therapeutics. The company was founded by Jun Hayashi, Ginette Serrero, and Gordon H. Sato in June 2000 and is headquartered in Columbia, MD.